Omniab, Inc. · NASDAQ:OABI
Omniab — PEGS Boston 2025
32 slides from Omniab's conference presentation, May 13, 2025
Slide 1: xPloration\u00ae: Simplifying Deep Antibody Mining for Maximum Impact
1 xPloration®: Simplifying Deep Antibody Mining for Maximum Impact Bob Chen, PhD VP, Discovery Systems May 13, 2025
Slide 2: OmniAb Enables Innovative Antibody Therapeutics
OmniAb Enables Innovative Antibody Therapeutics 2 AS OF 3/31/2025 Overview Clinical and Commercial-Stage Partner Pipeline(1)(2) 95 DF Active Partners 378 DF Active Programs 33 DF Active Clinical Programs and Approved Products Only programs with downstream economics are shown (1) Program placement is
Slide 3: OmniAb Technologies
3 OmniAb Technologies TECHNOLOGY OFFERINGS ADDRESS THE MOST CRITICAL CHALLENGES OF ANTIBODY DISCOVERY Create Screen Deliver Create Diverse Repertoires of Screen Millions of Cells to Find Further Characterize, Select and Optimize High-Quality Antibodies Potential Therapeutic Candidates the Right Ther
Slide 4: xPloration\u00ae: AI-Driven Deep Functional Screening
4 xPloration®: AI-Driven Deep Functional Screening HIGH THROUGHPUT, SIMPLE, AND ROBUST PLATFORM TECHNOLOGY Evaluate millions of variants and isolate thousands of positives in minutes Microcapillary Array
Slide 5: xPloration\u00ae: Simplifying Antibody Screening
5 xPloration®: Simplifying Antibody Screening Immunization Isolate B-cells Expression Validation Sequence Bioinformatics Hybridoma Workflow Fusion Screen B-cell Enrichment Single-cell Workflow optional NGS Our powerful single B-cell screening platform xPloration® bypasses bottlenecks of hybridoma wo
Slide 6: 1. Load Cells into >1 Million Microcapillaries
6 1. Load Cells into >1 Million Microcapillaries Microcapillary array Assays Cell binding Selective binding Unique through-hole format B cell Target cell B cell Protein beads Epitope blocking Affinity 1.5 million, 40 µm diameter microcapillaries B cell Benchmark B cell Protein beads
Slide 7: 2. Analyze Each Microcapillary
7 2. Analyze Each Microcapillary Computer vision hit detection Input Prediction Input Prediction Input Prediction
Slide 8: 3. Rapidly Recover the Best Hits
8 3. Rapidly Recover the Best Hits Laser extraction DF Rapid, precise, touchless recovery Single cell Extract up to barcoding for DF VH + VL 10,000 DF pairing pooled cells 1x speed video of laser recovery
Slide 9: Flexible Assays Unlock Desired Activity Profile
9 Flexible Assays Unlock Desired Activity Profile Case study 1 Case study 2 Deep mining of common light chain Discovering a competitor for a platform benchmark antibody Cell binding Epitope blocking B cell Target cell Selective binding B cell Benchmark B cell Protein beads
Slide 10: Case Study 1
10 Case Study 1 Discovering NK cell engager arm for bispecific antibody
Slide 11: Project Background
11 Project Background Target • NKp46 (NCR1, CD335) is a 46-kDa glycoprotein • No statistically significant downregulation of NKp46 on both NK and T cells has been observed in many cancers • Potential target for a NK cell engager From PDB 1OLL Discover antibodies using OmniFlic for bispecific antibod
Slide 12: Multi-Parameter Screening: Multiplex Phenotypic Data
12 Multi-Parameter Screening: Multiplex Phenotypic Data Selective binding of target on beads Selective binding of target cell Target Target B cell Control B cell Control BF Binding BF Binding Binding BF Binding Binding to Target Binding to Control Control
Slide 13: OmniFlic\u00ae Screening Summary
13 OmniFlic® Screening Summary Screen Type # Cells Screened # Hits Antigen on beads 5M 1429 1 Cells 7.7 M 345 Antigen on beads 3.7 M 751 2 Cells 3.7 M 158 Antigen on beads 3.7 M 308 3 Cells 3.7 M 33 Total 27.5 M 3024 Processed with pooled NGS for 1375 unique sequences Synergy between OmniFlic, xPlor
Slide 14: OmniFlic\u00ae Repertoire Space
14 OmniFlic® Repertoire Space Bead screen Cell screen
Slide 15: Bioinformatics-Aided Antibody Selection
15 Bioinformatics-Aided Antibody Selection Post-sort selection of activity profile Diversity All clones Cell + Protein binder All Cell binder Method A Count Method B Cell binder only Protein binder only Lineages Clone selection considerations: • Maximize coverage of sequence diversity Simple paralle
Slide 16: Discovery of Large Panel of NKp46 Binders
16 Discovery of Large Panel of NKp46 Binders # Selected Clones Expression (%) Binding (%) <10 nM (%) 301 95.7 84.7 20.1 Top 4 Lineages xPloration® deep mining leads to diverse antibodies
Slide 17: Case Study 2
17 Case Study 2 Discovering antibodies that block clinical benchmark
Slide 18: Project Background
18 Project Background Target • Interferon alpha-2 (IFNα2) is an inflammatory cytokine • Target for lupus and other autoimmune diseases • Known clinical benchmark targeting proven epitope From PDB 1ITF Discover antibodies that compete with known clinical benchmark
Slide 19: Multi-Parameter Screening: Cross-Blocking Assay
19 Multi-Parameter Screening: Cross-Blocking Assay Blocking Hit Non-blocking hit x Binder Blocker Binder Non-blocker Secreted Benchmark Secreted Antibody Antibody Antibody
Slide 20: Cloning and NGS Synergy
20 Cloning and NGS Synergy xPloration Cloning Expression Sequence Assay A A A # Info NGS • Single framework enables facile cloning • NGS builds upon assay data and sanger sequencing to expand repertoire space # Info
Slide 21: SPR Validates Screening Activity
21 SPR Validates Screening Activity Pre-complex assay on Carterra LSA Summary From xPloration to SPR Validation IFNα2 + blocker 83% complex DF Accuracy Up to 77 DF 3 DF Blocker Non-Blocker Antibodies Bead types xPloration® blocking assay enables focused epitope targeting
Slide 22: Differentiated advantages
22 Differentiated advantages xPloration
Slide 23: xPloration Offers Precision Discovery at Scale
23 xPloration Offers Precision Discovery at Scale POWERFUL SCREENING AND FAST RECOVERY RATE Find the rare clone Mine hits deeply AI-based screen > 1 million Rapidly sort 10,000 of live cells via touchless method Merging industry leading throughput with precision for impactful results
Slide 24: Technology Matured Through Campaigns
24 Technology Matured Through Campaigns Campaigns Types of Targets 400+ Multi-Tm [GPCR, Ion DF Channel, Transporter] Screens Soluble DF Receptors ~3DF B ~60,000 DF Intracellular Cells screened Hits extracted
Slide 25: xPloration: Simple and Robust for Maximum Uptime
25 xPloration: Simple and Robust for Maximum Uptime ROBUST, LOW MAINTENANCE USER EXPERIENCE No fluidics Robust components Maximized uptime + = No clogs or leaks Proven components Minimal maintenance Simplicity and robustness from installation to training to campaigns
Slide 26: Simplicity Enables 3-5 Runs Daily
26 Simplicity Enables 3-5 Runs Daily 9 am 10 am 11 am 12 pm 1 pm 2 pm 3 pm 4 pm Off instrument Load ▪ Screen an immunization campaign in 1-2 days Incubate 1.5 hr ▪ Short run times reduces cell viability concerns Analyze Recover Run 1 On instrument Run 2 Run 3 Run 4
Slide 27: Maximize Discovery Minimize Complexity
27 Maximize Discovery Minimize Complexity
Slide 28: Maximize Diversity Minimize Frustrations
28 Maximize Diversity That matches target profile Minimize Frustrations Of users
Slide 29: Maximize Success Minimize Failure
29 Maximize Success Of each campaign Minimize Failure modes
Slide 30: xPloration Delivers Maximum Impact For Our Partners
30 xPloration Delivers Maximum Impact For Our Partners ▪ Enables deep mining of immunized repertoires with flexible assays to find the right antibody ▪ Excel at rare hit selection, large repertoire analysis, and screening for membrane proteins ▪ Validated workflows for all OmniAb animals available f
Slide 31: Launching Partner Access Program
31 Launching Partner Access Program ▪ Available for purchase by OmniAb partners ▪ Enhance your capabilities in antibody discovery! ▪ Demo at Booth #305
Slide 32: Omni >
Omni >